Developer docs
API playgroundTry for free, no card

Search company profiles

Kimera Labs

Full company profile

uuid0006y5n

Namestring
Kimera Labs
Legal namestring
Kimera Labs, Inc.
Websiteurl
kimeralabs.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Kimera Labs is a clinical-stage biotechnology laboratory headquartered in a 27,000 sq. ft. cGMP-certified facility in Miramar, Florida, specializing in the production of pharmaceutical-grade mesenchymal stem cell (MSC)-derived exosomes. Founded by Duncan Ross, Ph.D. and operating since 2012, the company isolates exosomes from cultured perinatal (placental) MSCs using a proprietary serial purification process and xeno-free, chemically defined media, distinguishing its workflow from tissue-processing or serum-based methods. The product portfolio spans commercial cosmetic topical lines — Kiara (hair vitality), Vive, and Luxir — alongside research-grade MSC exosomes and topical amino-acid ingredients marketed to aesthetic and clinical-research customers.

Technically, Kimera operates an advanced characterization stack to verify exosome identity and purity, including ONI STORM super-resolution fluorescence microscopy for tetraspanin biomarker visualization (CD9, CD63, CD81, CD73), Malvern NanoSight NS300 Nanoparticle Tracking Analysis, Agilent HPLC, Illumina NextSeq 1000 RNA sequencing, ELISA, AFM, and TEM. Manufacturing is conducted inside ISO 7 cleanrooms with ISO 5 laminar flow glovebox isolators under cGMP. The company holds an active FDA IND for a Phase I/IIa trial of its MSC exosomes in mild-to-moderate COVID-19 (Phase I safety readout targeted for Q3 2026) and has implemented ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 certifications, following closure of a September 2023 FDA Warning Letter tied to earlier unapproved products (XoGlo, XoGlo Pro, Amnio2X).

The business model is B2B and sales-led: products are sold to aesthetic professionals, dermatologists, oncologists, and medical researchers through inquiry-based engagement, facility tours, and on-campus educational seminars rather than consumer retail. Revenue is generated through one-time product sales of cosmetic lines and research-grade exosomes at undisclosed quote-based pricing. Geographic scope is currently USA-only, with no disclosed external funding rounds and no named institutional investors identified.

Short descriptiontext

Kimera Labs is a clinical-stage biotechnology laboratory in Miramar, Florida that produces pharmaceutical-grade placental MSC-derived exosomes and topical cosmetic lines (Kiara, Vive, Luxir) for aesthetic professionals and clinical researchers, operating from a 27,000 sq. ft. cGMP facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiramar Beach, United States
HQ citystring
Miramar Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome biotechnology, stem cell research, regenerative medicine, cosmetic exosomes, cGMP manufacturing
Industry1 code
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Exosome Biotechnology Products
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1MSC Exosome Product Sales
TypeOne Time License
Description

Sale of pharmaceutical-grade MSC-derived exosome products for cosmetic applications and clinical research. Products include Kiara (hair vitality), Vive (topical cosmetic), and research-grade exosomes sold to practitioners and medical facilities.

kimeralabs.com
2Cosmetic Product Lines
TypeOne Time License
Description

Commercial topical cosmetic product lines including Kiara, Luxir, and Vive marketed to aesthetic professionals.

kimeralabs.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Kiara
Description

Hair vitality product utilizing placental MSC-derived extracellular vesicles for hair restoration.

kimeralabs.com
+2 more records
Core offering1 text field

Kimera Labs produces pharmaceutical-grade, mesenchymal stem cell (MSC)-derived exosome products for cosmetic, aesthetic, and clinical/research applications. The company isolates and manufactures exosomes using proprietary processes in ISO 7 cleanroom, cGMP-compliant facilities, supplying aesthetic practitioners, medical facilities, and researchers with standardized biologic products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully closed FDA Warning Letter issued September 1, 2023 after demonstrating corrective actions and ceasing unapproved product distribution during August 2024 follow-up inspection.
+2 more records
Product overview1 text field

Kimera Labs operates as a clinical-stage biotechnology company specializing in placental mesenchymal stem cell (MSC)-derived exosome products. The company produces pharmaceutical-grade MSC exosomes from isolated cell cultures using chemically defined, xeno-free media in cGMP-compliant facilities. The product portfolio includes: (1) Kiara, a hair vitality cosmetic product; (2) Vive and Luxir, topical cosmetic product lines; (3) MSC Exosomes for research and clinical applications; and (4) amino acid ingredients for topical formulations. Previously marketed XoGlo, XoGlo Pro, and Amnio2X products have been discontinued following FDA regulatory action. The company holds an active IND with Phase I safety trials and is pursuing clinical development for dermatology and oncology applications.

Product and service5 records
1Kiara
CategoryCosmetic Exosome Products
2Vive
CategoryCosmetic Exosome Products
3Luxir
CategoryCosmetic Exosome Products
4MSC Exosomes
CategoryClinical Exosome Products
5Amino Acids (Topical)
CategoryCosmetic Ingredients
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kimera Labs

Exosome Biotechnology Productskimeralabs.com

Kimera Labs is a clinical-stage biotechnology laboratory in Miramar, Florida that produces pharmaceutical-grade placental MSC-derived exosomes and topical cosmetic lines (Kiara, Vive, Luxir) for aesthetic professionals and clinical researchers, operating from a 27,000 sq. ft. cGMP facility.

What Kimera Labs does

Kimera Labs is a clinical-stage biotechnology laboratory headquartered in a 27,000 sq. ft. cGMP-certified facility in Miramar, Florida, specializing in the production of pharmaceutical-grade mesenchymal stem cell (MSC)-derived exosomes. Founded by Duncan Ross, Ph.D. and operating since 2012, the company isolates exosomes from cultured perinatal (placental) MSCs using a proprietary serial purification process and xeno-free, chemically defined media, distinguishing its workflow from tissue-processing or serum-based methods. The product portfolio spans commercial cosmetic topical lines — Kiara (hair vitality), Vive, and Luxir — alongside research-grade MSC exosomes and topical amino-acid ingredients marketed to aesthetic and clinical-research customers.

Technically, Kimera operates an advanced characterization stack to verify exosome identity and purity, including ONI STORM super-resolution fluorescence microscopy for tetraspanin biomarker visualization (CD9, CD63, CD81, CD73), Malvern NanoSight NS300 Nanoparticle Tracking Analysis, Agilent HPLC, Illumina NextSeq 1000 RNA sequencing, ELISA, AFM, and TEM. Manufacturing is conducted inside ISO 7 cleanrooms with ISO 5 laminar flow glovebox isolators under cGMP. The company holds an active FDA IND for a Phase I/IIa trial of its MSC exosomes in mild-to-moderate COVID-19 (Phase I safety readout targeted for Q3 2026) and has implemented ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 certifications, following closure of a September 2023 FDA Warning Letter tied to earlier unapproved products (XoGlo, XoGlo Pro, Amnio2X).

The business model is B2B and sales-led: products are sold to aesthetic professionals, dermatologists, oncologists, and medical researchers through inquiry-based engagement, facility tours, and on-campus educational seminars rather than consumer retail. Revenue is generated through one-time product sales of cosmetic lines and research-grade exosomes at undisclosed quote-based pricing. Geographic scope is currently USA-only, with no disclosed external funding rounds and no named institutional investors identified.

Kimera Labs firmographics

Firmographics
Name
Kimera Labs
Legal name
Kimera Labs, Inc.
Website
https://kimeralabs.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Kimera Labs is a clinical-stage biotechnology laboratory in Miramar, Florida that produces pharmaceutical-grade placental MSC-derived exosomes and topical cosmetic lines (Kiara, Vive, Luxir) for aesthetic professionals and clinical researchers, operating from a 27,000 sq. ft. cGMP facility.
Ownership category
akta.pro rank

Kimera Labs industry classification

Industry
Product category
Exosome Biotechnology Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Exosome biotechnology
  • Stem cell research
  • Regenerative medicine
  • Cosmetic exosomes
  • CGMP manufacturing

Where Kimera Labs is headquartered

Location

Headquarters

HQ city
Miramar Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kimera Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. MSC Exosome Product Sales: Sale of pharmaceutical-grade MSC-derived exosome products for cosmetic applications and clinical research. Products include Kiara (hair vitality), Vive (topical cosmetic), and research-grade exosomes sold to practitioners and medical facilities.
  2. Cosmetic Product Lines: Commercial topical cosmetic product lines including Kiara, Luxir, and Vive marketed to aesthetic professionals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Kimera Labs product offering

Product offering

Core offering

Kimera Labs produces pharmaceutical-grade, mesenchymal stem cell (MSC)-derived exosome products for cosmetic, aesthetic, and clinical/research applications. The company isolates and manufactures exosomes using proprietary processes in ISO 7 cleanroom, cGMP-compliant facilities, supplying aesthetic practitioners, medical facilities, and researchers with standardized biologic products.

Product overview

Kimera Labs operates as a clinical-stage biotechnology company specializing in placental mesenchymal stem cell (MSC)-derived exosome products. The company produces pharmaceutical-grade MSC exosomes from isolated cell cultures using chemically defined, xeno-free media in cGMP-compliant facilities. The product portfolio includes: (1) Kiara, a hair vitality cosmetic product; (2) Vive and Luxir, topical cosmetic product lines; (3) MSC Exosomes for research and clinical applications; and (4) amino acid ingredients for topical formulations. Previously marketed XoGlo, XoGlo Pro, and Amnio2X products have been discontinued following FDA regulatory action. The company holds an active IND with Phase I safety trials and is pursuing clinical development for dermatology and oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Kiara: Hair vitality product utilizing placental MSC-derived extracellular vesicles for hair restoration.
  • Vive
  • Luxir

Products and services

  • Kiara
  • Vive
  • Luxir
  • MSC Exosomes
  • Amino Acids (Topical)

Quantifiable outcome

  • Successfully closed FDA Warning Letter issued September 1, 2023 after demonstrating corrective actions and ceasing unapproved product distribution during August 2024 follow-up inspection.
  • +2 more outcomes

Companies that use Kimera Labs

Customer profile

Segments4 records

Ideal customer profiles2 records

Kimera Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Kimera Labs partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Kimera Labs competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Kimera Labs social profiles

Digital presence

Kimera Labs compliance and trust

Trust signal

Compliance4 records

Kimera Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kimera Labs leadership team

Management profile

Number of profiles

Profiles1 record

Kimera Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kimera Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kimera Labs

What does Kimera Labs do?

Kimera Labs produces pharmaceutical-grade, mesenchymal stem cell (MSC)-derived exosome products for cosmetic, aesthetic, and clinical/research applications. The company isolates and manufactures exosomes using proprietary processes in ISO 7 cleanroom, cGMP-compliant facilities, supplying aesthetic practitioners, medical facilities, and researchers with standardized biologic products.

Is Kimera Labs a public or private company?

Kimera Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kimera Labs founded?

Kimera Labs was founded in 2015. It employs 11 to 50 people.

Where is Kimera Labs based?

Kimera Labs is headquartered in Miramar Beach, United States, in the North America region.

How does Kimera Labs make money?

Two revenue lines are on record. MSC Exosome Product Sales are the primary driver. The others are cosmetic Product Lines.

Does Kimera Labs have an API?

No public API is recorded for Kimera Labs.

What industry is Kimera Labs in?

Kimera Labs's product category is Exosome Biotechnology Products. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
U.S. Food and Drug AdministrationKimera Labs, Inc. - 649343 - 09/01/2023The FDA issued a Warning Letter to Kimera Labs, Inc. on September 1, 2023, following an inspection in July 2022 at the company's facility in Miramar, Florida, documenting that the company manufactured and distributed unapproved exosome products (XoGlo®, XoGlo®Pro) and an amniotic fluid product (Amnio2X®) to practitioners and medical facilities throughout the United States. The FDA cited significant deviations from current good manufacturing practice (CGMP) requirements involving over 37,000 vials manufactured between April 2020 and June 2022, including failures to validate aseptic processes, inadequate sterility testing, and distribution of a lot with a positive sterility result. The agency is requesting a response within 15 working days and warning that failure to adequately address the violations may result in regulatory action including seizure and/or injunction.U.S. Food and Drug AdministrationKimera Labs, Inc. - 649343 - 06/12/2026The FDA's Center for Biologics Evaluation and Research has closed out a Warning Letter issued to Kimera Labs, Inc. on September 1, 2023, after evaluating the company's corrective actions submitted between September 2023 and March 2024. A follow-up inspection conducted between August 19-21, 2024 confirmed that Kimera Labs had ceased manufacturing, sale, and distribution of its Amnio2X®, XoGlo®, and XoGlo®Pro products and removed them from all sales channels. The agency stated this closure does not preclude future regulatory action and that continued compliance with the Federal Food, Drug, and Cosmetic Act is expected.AijournKimera Labs Implements ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 Across Its Miramar Manufacturing FacilityKimera Labs, Inc. has implemented three ISO quality management certifications — ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 — at its 27,000-square-foot manufacturing facility in Miramar, Florida. The certifications apply across both the company's investigational manufacturing program and its commercial cosmetic product lines (Kiara, Luxir, and Vive), establishing a unified quality system governing IND-regulated manufacturing and GMP-compliant cosmetic production. Kimera Labs holds an active Investigational New Drug application with a Phase I safety trial scheduled for completion by the end of Q3/2026.PR NewswireKimera Labs Implements ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 Across Its Miramar Manufacturing FacilityKimera Labs, a clinical-stage biotechnology company specializing in placental mesenchymal stem cell-derived exosomes, has implemented three ISO quality management certifications across its 27,000-square-foot Miramar, Florida facility. The certifications — ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 — apply to both the company's investigational manufacturing program and its commercial cosmetic product lines, including Kiara, Luxir, and Vive. The move reinforces the company's quality framework as it operates under an active IND with a Phase I safety trial scheduled for completion by the end of Q3/2026.Data Insights MarketExosomes Skincare Analysis Report 2026: Market to Grow by a CAGR of XX to 2034, Driven by Government Incentives, Popularity of Virtual Assistants, and Strategic PartnershipsA market research report projects the global exosomes skincare market to grow from $500 million in 2025 to approximately $1.8 billion by 2033, representing a compound annual growth rate of 34.22% during the forecast period (2026-2034). Key drivers of this growth include rising consumer demand for anti-aging solutions, increased awareness of exosome efficacy in skin rejuvenation, and technological advancements in exosome extraction and formulation, while challenges include high production costs and stringent regulatory requirements. The anti-aging application segment and North America are expected to dominate the market, with key players including ExoCoBio, Kimera Labs, Xollent Biotech, Paradise Life Technology, and Xiamen Aisai Biotechnology driving innovation through R&D and strategic partnerships.Longevity.TechnologyArt meets science to tackle diseases of agingThe Alliance for Longevity Science, Arts & Entertainment (ALSAE) has launched as a nonprofit to bridge the gap between longevity science and mainstream culture by partnering with artists, filmmakers, and musicians to translate complex aging research into compelling public narratives. The organization, whose founding partners include XPRIZE Healthspan, the Aoki Foundation, and the Buck Institute for Research on Aging, plans to host private retreats for Hollywood showrunners at leading longevity research centers starting next year. ALSAE's partner organizations include biotech companies Cyclarity Therapeutics, Kimera Labs, and Intervene Immune, as well as Methuselah Foundation as its fiscal sponsor.openPR.comExosomes Skincare Market Set to Witness Significant Growth by 2025-2032 | ExoCoBio, Kimera Labs, Xollent BiotechThe global exosomes skincare market is projected to grow from USD 417.8 million in 2025 to USD 809.5 million by 2032, a CAGR of 9.9%. The report also covers key players, segmentation, and regional outlook.Global Growth InsightsExosomes Skincare Market Size, Trends & CAGR, 2035The global exosomes skincare market was valued at USD 307.6 million in 2025 and is projected to reach USD 769.3 million by 2035, growing at a CAGR of 9.6%, according to a market research report. Asia-Pacific leads the market with a 39% share, followed by North America at 26% and Europe at 23%, with South Korea and Japan driving innovation and clinical adoption. Key players including ExoCoBio, Kimera Labs, Xollent Biotech, Paradise Life Technology, and Xiamen Aisai Biotechnology Co., Ltd. are investing in product launches and partnerships, though the market faces challenges from regulatory ambiguity and production scalability issues.PR NewswireKimera® Labs Inc. veröffentlicht neuartiges Gehirn-Targeting von Exosomen in Nature Scientific ReportsKimera Labs Inc. announced the publication of research in Nature Scientific Reports demonstrating that its MSC-exosomes can cross the blood-brain barrier using transcranial low-intensity focused ultrasound in a rat model, a collaboration with scientists from City of Hope and the Regenesis Project. The in-vivo animal studies conducted at City of Hope showed statistically significant delivery of exosomes to targeted brain regions. The company, which received FDA IND approval in May 2023 for Phase I/IIa human clinical trials in post-Covid patients, plans to file further INDs for additional neurological indications.PR NewswireKimera® Labs Inc. publie un nouveau rapport sur le ciblage cérébral des exosomes dans Nature Scientific ReportsKimera® Labs Inc., a clinical-stage biotechnology company, announced the publication of a peer-reviewed study in Nature Scientific Reports demonstrating that its MSC-derived exosomes can cross the blood-brain barrier using transcranial focused ultrasound in a rat model, with statistically significant penetration into targeted brain regions. The study was conducted by scientists from City of Hope, Regenesis Project, and Kimera Labs as a collaborative effort spanning over two years of research and funding. The company views this as a material breakthrough in targeted brain delivery for neurology and plans to submit multiple clinical trial applications targeting various neuronal dysfunction indications for future human trials.